Overview
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2023-12-01
2023-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After completion of ZGJAK018 study, the study will be directly extend with an "open-label design".Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Criteria
Inclusion Criteria:- Subjects voluntarily sign the informed consent form.
- Patients who participated in ZGJAK018.
Exclusion Criteria:
- Subjects who are unsuitable to the trial, as identified by the investigator.